Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453

Last updated date
Study Location
Retinal Consultants of Alabama P.C.
Birmingham, Alabama, 35233, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV)

- Presence of BRAF V600E or V600K mutation in tumor tissue prior to randomization

- Naïve untreated patients or patients who have progressed on or after prior first line immunotherapy for resectable locally advanced or metastatic melanoma; prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors

- Evidence of at least one measurable lesion as detected by radiological or photographic methods

- ECOG performance status of 0 or 1

- Adequate bone marrow, organ function, cardiac and laboratory parameters

- Normal functioning of daily living activities

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any untreated central nervous system (CNS) lesion


- Uveal and mucosal melanoma


- History of leptomeningeal metastases


- History of or current evidence of central serous retinopathy (CSR), retinal vein
occlusion (RVO) or history of retinal degenerative disease


- Any previous systemic chemotherapy treatment, extensive radiotherapy or
investigational agent other than immunotherapy, or patients who have received more
than one line of immunotherapy for locally advanced unresectable or metastatic
melanoma; Ipilimumab (adjuvant) or other immunotherapy treatment must have ended at
least 6 weeks prior to randomization


- History of Gilbert's syndrome


- Prior therapy with a BRAF inhibitor and/or a MEK- inhibitor


- Impaired cardiovascular function or clinically significant cardiovascular diseases


- Uncontrolled arterial hypertension despite medical treatment


- HIV positive or active Hepatitis B, and/or active Hepatitis C


- Impairment of gastrointestinal function


- Patients with neuromuscular disorders that are associated with elevated CK


- Pregnant or nursing (lactating) women


- Medical, psychiatric, cognitive or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study


Other protocol-defined inclusion/exclusion criteria may apply

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Aurora, Colorado
  11. Boulder, Colorado
  12. Colorado Springs, Colorado
  13. Denver, Colorado
  14. Lakewood, Colorado
  15. Parker, Colorado
  16. Pueblo, Colorado
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Goshen, Indiana
  22. Goshen, Indiana
  23. Grand Rapids, Michigan
  24. Grand Rapids, Michigan
  25. Grand Rapids, Michigan
  26. Jackson, Mississippi
  27. Jackson, Mississippi
  28. Hackensack, New Jersey
  29. Rochester, New York
  30. Dallas, Texas
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. Alexandria, Virginia
  35. Arlington, Virginia
  36. Fairfax, Virginia
  37. Fairfax, Virginia
  38. Fairfax, Virginia
  39. Falls Church, Virginia
  40. Gainesville, Virginia
  41. Leesburg, Virginia
  42. Woodbridge, Virginia
  43. Wenatchee, Washington
  44. Caba, Buenos Aires
  45. Buenos Aires, Ciudad Autónoma DE Buenosaires
  46. Buenos Aires, Ciudad Autónoma DE Buenosaires
  47. Buenos Aires, Ciudad Autónoma DE Buenosaires
  48. Buenos Aires, Ciudad Autónoma DE Buenosaires
  49. Buenos Aires, Ciudad Autónoma DE Buenosaires
  50. Buenos Aires, Ciudad Autónoma DE Buenosaires
  51. Gateshead, New South Wales
  52. Southport, Queensland
  53. Southport, Queensland
  54. Southport, Queensland
  55. Woolloongabba, Queensland
  56. Prahran, Victoria
  57. Nedlands, Western Australia
  58. Recife, Pernambuco
  59. Ijuí, RIO Grande DO SUL
  60. Porto Alegre, RIO Grande DO SUL
  61. Barretos, SAO Paulo
  62. Natal,
  63. Rio de Janeiro,
  64. Sao Paulo,
  65. Calgary, Alberta
  66. Toronto, Ontario
  67. Toronto, Ontario
  68. Toronto, Ontario
  69. Montreal, Quebec
  70. Montreal, Quebec
  71. Montreal, Quebec
  72. Montreal, Quebec
  73. Québec, Quebec
  74. Bogotá, Distrito Capital DE Bogotá
  75. Bogotá, Pbx (57-1)
  76. Brno, Jihomoravský KRAJ
  77. Praha 10, Praha, Hlavní Mesto
  78. Praha 2, Praha, Hlavní Mesto
  79. Brno,
  80. Olomouc,
  81. Ostrava Poruba,
  82. Praha,
  83. Nice, Alpes-maritimes
  84. Bordeaux, Gironde
  85. Grenoble, Isère
  86. Reims, Marne
  87. Lille, Nord
  88. Lyon, Rhone
  89. Lyon, Rhône
  90. Le Mans, Sarthe
  91. Villejuif, Val-de-marne
  92. Boulogne-Billancourt,
  93. Lille,
  94. Lyon,
  95. Nice,
  96. Paris,
  97. Paris,
  98. Paris,
  99. Paris,
  100. Pierre-bénite,
  101. Strasbourg,
  102. Templemars,
  103. Villejuif,
  104. Freiburg im Breisgau, Baden-württemberg
  105. Heidelberg, Baden-württemberg
  106. Mannheim, Baden-württemberg
  107. Tübingen, Baden-württemberg
  108. Ulm, Baden-württemberg
  109. München, Bayern
  110. Regensburg, Bayern
  111. Regensburg, Bayern
  112. Würzburg, Bayern
  113. Frankfurt, Hessen
  114. Kassel, Hessen
  115. Kassel, Hessen
  116. Buxtehude, Niedersachsen
  117. Buxtehude, Niedersachsen
  118. Bonn, Nordrhein-westfalen
  119. Minden, Nordrhein-westfalen
  120. Minden, Nordrhein-westfalen
  121. Mainz, Rheinland-pfalz
  122. Magdeburg, Sachsen-anhalt
  123. Dresden, Sachsen
  124. Leipzig, Sachsen
  125. Berlin, Schleswig-holstein
  126. Luebeck, Schleswig-holstein
  127. Lübeck, Schleswig-holstein
  128. Berlin,
  129. Bonn,
  130. Bonn,
  131. Dresden,
  132. Dresden,
  133. Erfurt,
  134. Erfurt,
  135. Essen,
  136. Freiburg,
  137. Gera,
  138. Gera,
  139. Gera,
  140. Hamburg,
  141. Hannover,
  142. Hannover,
  143. Hannover,
  144. Heidelberg,
  145. Homburg,
  146. Kiel,
  147. Lübeck,
  148. Magdeburg,
  149. Magdeburg,
  150. Mainz,
  151. Mannheim,
  152. Minden,
  153. Münster,
  154. Nürnberg,
  155. Regensburg,
  156. Tübingen,
  157. Ulm,
  158. Ulm,
  159. Athens, Attiki
  160. Athens,
  161. Athens,
  162. Piraeus,
  163. Budapest,
  164. Budapest,
  165. Debrecen,
  166. Szolnok,
  167. Ramat Gan, Tel-aviv
  168. Haifa,
  169. Jerusalem,
  170. Torrette Site, Ancona
  171. Napoli, Campania
  172. Roma, Lazio
  173. Roma, Lazio
  174. Lecco, Lombardia
  175. Milan, Lombardia
  176. Monza, Lombardia
  177. Rozzano, Lombardia
  178. Rozzano, Lombardia
  179. Candiolo, Torino
  180. Pisa, Toscana
  181. Terni, Umbria
  182. Padua, Veneto
  183. Bari,
  184. Bergamo,
  185. Bologna,
  186. Genoa,
  187. Milano,
  188. Napoli,
  189. Padova,
  190. Pavia,
  191. Ragusa,
  192. Siena,
  193. Torino,
  194. Fukuoka-shi, Fukuoka
  195. Matsumoto, Nagano
  196. Chuo-ku, Tokyo
  197. Niigata,
  198. Osaka, Ôsaka
  199. Gangnam-Gu, Seoul Teugbyeolsi
  200. Songpa-Gu, Seoul Teugbyeolsi
  201. Seoul,
  202. Seoul,
  203. Seoul,
  204. Seoul,
  205. Mexico,
  206. Mexico,
  207. Nijmegen, Gelderland
  208. Heerlen, Limburg
  209. Amsterdam, Noord Holland
  210. Breda, Noord-brabant
  211. Eindhoven, Noord-brabant
  212. Veldhoven, Noord-brabant
  213. Zwolle, Overijssel
  214. Enschede,
  215. Groningen,
  216. Leiden,
  217. Maastricht,
  218. Rotterdam,
  219. Rotterdam,
  220. Sittard-Geleen,
  221. Oslo,
  222. Oslo,
  223. Oslo,
  224. Warsaw, Mazowieckie
  225. Warszawa, Mazowieckie
  226. Warszawa,
  227. Lisbon, Lisboa
  228. Porto, Proto
  229. Almada,
  230. Lisboa,
  231. Lisboa,
  232. Lisboa,
  233. Porto,
  234. Moscow,
  235. St. Petersburg,
  236. Singapore,
  237. Singapore,
  238. Singapore,
  239. Bratislava,
  240. Bratislava,
  241. Bratislava,
  242. Poprad,
  243. Pretoria,
  244. Pretoria,
  245. Jerez De La Frontera, Andalucía
  246. Oviedo, Asturias
  247. Barcelona, Cataluña
  248. El Palmar, Murcia
  249. Pamplona, Navarra
  250. Pamplona, Navarra
  251. Alicante,
  252. Badalona,
  253. Barcelona,
  254. Barcelona,
  255. Barcelona,
  256. Barcelona,
  257. Donostia-san Sebastián,
  258. Dos Hermanas,
  259. Granada,
  260. La Coruna,
  261. Lleida,
  262. Lleida,
  263. Madrid,
  264. Madrid,
  265. Madrid,
  266. Madrid,
  267. Majadahonda,
  268. Malaga,
  269. Sevilla,
  270. Sevilla,
  271. Sevilla,
  272. Valencia,
  273. Göteborg,
  274. Lund,
  275. Solna,
  276. Uppsala,
  277. Zurich, Zürich (DE)
  278. Bern,
  279. Zürich,
  280. Zürich,
  281. Zürich,
  282. Bornova,
  283. Izmir,
  284. Izmir,
  285. Cambridge, Cambridgeshire
  286. Preston, Lancashire
  287. London, London, CITY OF
  288. Guildford, Surrey
  289. Bebington, Wirral
  290. Sheffield, York
  291. Broomfield,
  292. Leeds,
  293. London,
  294. Manchester,
  295. Oxford,
  296. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159117
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
NCT01008527
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Official Title  ICMJE A 2-part Phase III Randomized, Open Label, Multicenter sSudy of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Brief Summary

This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.

Part 1:

Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:

  1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm)
  2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or
  3. vemurafenib 960 mg BID (denoted as vemurafenib arm)

Part 2:

Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms:

  1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or
  2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE
  • Drug: LGX818
    LGX818- Orally 100 mg and 50 mg capsules
  • Drug: MEK162
    MEK162- Orally 15 mg tablets
  • Drug: vemurafenib
    Tablets in bottles or blisters 240 mg
    Other Names:
    • Zelboraf
    • PLX4032
    • RO5185426
Study Arms  ICMJE
  • Experimental: LGX818 450 mg + MEK162
    LGX818 450 mg QD + MEK162 45 mg BID
    Interventions:
    • Drug: LGX818
    • Drug: MEK162
  • Active Comparator: Vemurafenib
    Vemurafenib 960 mg BID
    Intervention: Drug: vemurafenib
  • Experimental: LGX818 300 mg + MEK162
    LGX818 300 mg QD + MEK162 45 mg BID
    Interventions:
    • Drug: LGX818
    • Drug: MEK162
  • Experimental: LGX818
    LGX818 300 mg QD
    Intervention: Drug: LGX818
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: November 3, 2016)
921
Original Estimated Enrollment  ICMJE
 (submitted: July 24, 2013)
900
Estimated Study Completion Date  ICMJE August 31, 2022
Actual Primary Completion Date November 9, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV)
  • Presence of BRAF V600E or V600K mutation in tumor tissue prior to randomization
  • Naïve untreated patients or patients who have progressed on or after prior first line immunotherapy for resectable locally advanced or metastatic melanoma; prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors
  • Evidence of at least one measurable lesion as detected by radiological or photographic methods
  • ECOG performance status of 0 or 1
  • Adequate bone marrow, organ function, cardiac and laboratory parameters
  • Normal functioning of daily living activities

Exclusion Criteria:

  • Any untreated central nervous system (CNS) lesion
  • Uveal and mucosal melanoma
  • History of leptomeningeal metastases
  • History of or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or history of retinal degenerative disease
  • Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Ipilimumab (adjuvant) or other immunotherapy treatment must have ended at least 6 weeks prior to randomization
  • History of Gilbert's syndrome
  • Prior therapy with a BRAF inhibitor and/or a MEK- inhibitor
  • Impaired cardiovascular function or clinically significant cardiovascular diseases
  • Uncontrolled arterial hypertension despite medical treatment
  • HIV positive or active Hepatitis B, and/or active Hepatitis C
  • Impairment of gastrointestinal function
  • Patients with neuromuscular disorders that are associated with elevated CK
  • Pregnant or nursing (lactating) women
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study

Other protocol-defined inclusion/exclusion criteria may apply

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Brazil,   Canada,   Colombia,   Czechia,   France,   Germany,   Greece,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Mexico,   Netherlands,   Norway,   Poland,   Portugal,   Russian Federation,   Singapore,   Slovakia,   South Africa,   Spain,   Sweden,   Switzerland,   Turkey,   United Kingdom,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01909453
Other Study ID Numbers  ICMJE CMEK162B2301
C4221004 ( Other Identifier: Pfizer )
2013-001176-38 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP